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Human T cell leukemia virus type-I (HTLV-I) infection is associated with spontaneous T cell activation and
uncontrolled lymphocyte proliferation. An exacerbated type-1 immune response with production of pro-inflamma-
tory cytokines (interferon-γ  and tumor necrosis factor-α) is significantly higher in patients with myelopathy asso-
ciated to HTLV-I than in HTLV-I asymptomatic carriers. In contrast with HTLV-I, a chronic Schistosoma mansoni
infection is associated with a type-2 immune response with high levels of interleukin (IL-4, IL-5, and IL-10) and low
levels of IFN-γ. In this study, clinical and immunological consequences of the HTLV-I and S. mansoni infection were
evaluated. The immune response in patients with schistosomiasis co-infected with HTLV-I showed low levels of IL-5
(p < 0.05) in peripheral blood mononuclear cells cultures stimulated with S. mansoni antigen (SWAP) and de-
creased SWAP-specific IgE levels when compared with patients with only schistosomiasis (p < 0.05). Liver fibrosis
was mild in all HTLV-I co-infected patients. Immunological response was also compared in individuals who had
only HTLV-I infection with those who were co-infected with HTLV-I and helminths (S. mansoni and Strongyloides
stercoralis). In patients HTLV-I positive co-infected with helminths the IFN-γ levels were lower than in individuals
who had only HTLV-I. Moreover, there were fewer cells expressing IFN-γ and more cells expressing IL-10 in individu-
als co-infected with HTLV-I and helminths. These dates indicate that HTLV-I infection decrease type 2-response and
IgE synthesis and are inversely associated with the development of liver fibrosis. Moreover, helminths may protect
HTLV-I infected patients to produce large quantities of pro-inflammatory cytokines such as IFN-γ.
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The human T cell leukemia virus type-I (HTLV-I) is an
oncogenic exogenous retrovirus that infects between 10
and 20 million people worldwide (Edlich et al. 2000). HTLV-
I is the recognized cause of adult T-cell leukemia (ATL) as
well as HTLV-I-associated myelopathy/tropical spastic
paraparesis (HAM/TSP) (Osame et al. 1986, Uchiyama
1997), but other disorders have been associated with
HTLV-I infection. The immunological response in HTLV-I
infection is characterized by a spontaneous lymphopro-
liferation and an exaggerated T cell response with high
production of important inflammatory mediators of tissue
damage as interferon-γ (IFN-γ), tumor necrosis factor-α
(TNF-α) and interleukin (IL-6) (Nishimoto et al. 1990,
Kubota et al. 1998, Carvalho et al. 2001). Although the
pathogenesis of neurological disease associated to HTLV-
I is not completely understood, there are various evidences
that immunological response participate and is respon-
sible by inducing tissue damage (Hanon et al. 2000, Nagai
& Jacobson 2001, Osame 2002). By the other hand,
helminthes infections such as strongyloidiasis and in
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particular a chronic disease caused by infection with Schis-
tosoma mansoni are associated with a predominant anti-
inflammatory type-2 immune response with increased lev-
els of IL-4, IL-5 and IL-10 and low levels of IFN-γ (Araujo
et al. 1996, Finkelman et al. 1997). The high degree of in-
fection and the host’s immune reaction to parasite eggs
contribute to granuloma formation. Liver fibrosis is the
most important pathological finding in schistosomiasis,
being registered in about 5% of chronically S. mansoni
infected patients (Bina & Prata 2003). Although initial ex-
perimental studies suggested that type-1 cytokines were
associated with granulomatous reaction to S. mansoni
infection (Leptak & McKerrow 1997, Rezende et al. 1997),
its clear from current data that type-2 cytokines play a
primary role in inducing fibrosis, whereas the IFN-γ (type-
1 cytokine) acts as an endogenous down regulator of the
response (Wynn et al. 1994, Chiaramonte et al. 1999a,
Jankovic et al. 1999). Simultaneous infection between
HTLV-I and Strongyloides stercoralis decreases the pre-
dominant type-2 immune response in patients with
strongyloidiasis (Neva et al. 1998, Porto et al. 2001a) as
well as S. stercoralis-specific and total IgE antibodies
(Neva et al. 1998, Porto et al. 2001b). Moreover, co-infec-
tion with HTLV-I is also associated with disseminated and
recurrent strongyloidiais (Phelps et al. 1991, Newton et al.
1992). It is known that the prevalence of strongyloidiasis
is higher in HTLV-I infected patients than in seronegative
controls (Robinson et al. 1994, Hayashi et al. 1997). Based
on these observations one of the aims of this study was
to determine if HTLV-I infection decrease the type-2 im-
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mune response observed in patients with schistosomia-
sis and the impact of HTLV-I on the development of liver
fibrosis. Moreover, considering that pathogenesis of dis-
eases associated to HTLV-I is dependent of high produc-
tion of pro-inflammatory cytokines it was evaluated if co-
infection with S. mansoni and HTLV-I decrease the type-
1 immune response
MATERIALS AND METHODS
Patients’ selection - Patients were selected from the
HTLV-I clinic of the Hospital Universitário Professor
Edgard Santos, Federal University of Bahia, Brazil. The
clinic follows more than 500 HTLV-I infected individuals,
most of then referred from two blood banks in Salvador,
the capital of the state of Bahia. The diagnosis of HTLV-I
infection was confirmed by Western blot (HTLV blot 2.4,
Genelabs, Singapore). All patients admitted in the HTLV-
I clinic are asked to perform three stool examinations. From
500 HTLV-I infected individuals, 309 had stool examina-
tion. Frequency of S. mansoni infection was assayed in
309 HTLV-I positive individuals and 331 seronegative
blood donors were screened as negative controls also by
stool examination; 14 HTLV-I positive patients had S.
stercoralis larvae in their stool examination and all of them
participated of the study. S. mansoni eggs were found in
26 HTLV-I infected individuals, but only 22 of them ac-
cepted to participate in the study.  The diagnosis of schis-
tosomiasis was made by a positive fecal examination for
eggs by Hoffman technique and the criterion for a diag-
nosis of strongyloidiasis was a positive fecal examination
for larvae by the Baermann concentration technique. Forty-
four (n = 44) patients with S. mansoni without HTLV-I
infection were selected from an existing cohort of patients
from an area endemic for S. mansoni infection (Caatinga
do Moura, Bahia). These patients were used to select a
ratio of 2 to 1 by matching age and sex with the group of
patients with co-infection. Clinical history and a complete
physical examination and abdominal ultrasound were per-
formed in both groups with S. mansoni infection (HTLV- I
positive and negative).
Neurological exam - Motor dysfunction was deter-
mined by Osame’s Motor Disability Score (OMDS) (Izumo
et al. 1996) and Expanded Disability Status Scale (EDSS)
(Kurtzke 1983). Patients with HAM/TSP had a marked
neurological impairment with EDSS ≥ 3 and OMDS ≥ 1
and all asymptomatic subjects had OMDS and EDSS of
zero. Based on exclusion criteria that included the use of
antiviral drugs or immunomodulators in the previous 90
days, co-infection with HIV, HCV or hepatitis B and pres-
ence of helminthes infection or other neurological dis-
eases, 17 patients with HAM/TSP performed immunologi-
cal evaluation. Thirty-six HTLV-I asymptomatic carriers,
without clinical manifestations associated with HTLV-I
were also selected. Healthy University Hospital employ-
ees who were seronegative for HTLV-I and seronegative
normal donors without helminthes infection were used as
negative controls.
The Ethical Committee of the Hospital Universitário
Professor Edgard Santos approved this study and in-
formed consent was obtained from all prospectively en-
rolled patients.
Cell preparation and cytokine determination - Pe-
ripheral blood mononuclear cells (PBMC) were obtained
by density gradient centrifugation using lymphocyte sepa-
ration media (LSM; Organon Teknika Coorporation,
Durham, NS, US). PBMC were cultivated in RPMI 1640
(Gibco, Grand Island, NY, US) plus 10% heat inactivated
human AB Rh+ serum (Sigma Chemical Co., St. Louis, MO),
antibiotics and glutamine (complete media) and adjusted
to 3 x 106 cells/ml in complete media. The cells were cul-
tured unstimulated or stimulated with 2 mg/ml soluble adult
S. mansoni worm antigen (SWAP) when patients were
co-infected with S. mansoni. All cultures were incubated
at 37°C in 5 % CO2 atmosphere for 72 h until supernatant
fluids were collected. IFN-γ and IL-5 levels were mea-
sured by sandwich ELISA technique (R&D system, Min-
neapolis, MN) and the results were expressed as pg/ml
using a standard curve generated using recombinant
cytokines.
 Flow cytometric analysis (FACS) - FACS was per-
formed after 20 h of incubation. Briefly, the PBMC were
immunophenotyped by double immunofluorescence us-
ing a FACScalibor flow cytometer and a panel of phyco-
erythrin (PE)-conjugated monoclonal antibodies. In all
cases the cells were double stained for cytokine and for
cell surface markers. Specifically the total percentage of
cells producing IFN-γ and IL-10 was assayed. In all cases,
30,000 gates events were acquired for later analysis due
to the low frequency of positive events being analyzed.
IgE specific to S. mansoni antigen - Analysis of IgE
specific to SWAP was performed by ELISA as previously
described (Souza-Atta et al. 1999). The ELISA was devel-
oped with 100 µl of p-nitrophenyl phosphate and the ab-
sorbance changes (optical density, OD) were measured
by a spectrophotometer at 405 nm. The cut-offs of the
immunoassay were determined using the mean plus 3 SD
of the absorbance obtained with serum from 15 healthy
individuals.
Ultrasonography - Ultrasonography examination was
performed with the Quantum 2000 Siemens ultrasound with
a convex transductor of 3.5 Mhz, according to a previ-
ously published technique (Abdel-Wahab et al. 1992).
Grading of hepatic fibrosis was determined according with
WHO criteria established in 1993 and previously revali-
dated (de Jesus et al. 2000). Patients were classified in
four different degrees according to the mean thickness of
four portal tracts after the first division from the right and
left branches of portal vein.
Statistical analysis - A non-parametric Mann-Whitney
U Test was used to evaluate differences among the groups.
Fisher’s exact test was used to compare proportions.
These statistical analyses were performed using the pro-
gram Instat for Windows. An alpha (α) of 5% was consid-
ered significant.
RESULTS
To determine if HAM/TSP patients and asymptomatic
subjects produce different levels of IFN-γ, this cytokine
was measured in supernatants of unstimulated cultures
of HTLV-I infected groups and compared with negative
controls. There was a high variability in IFN-γ levels in
asymptomatic carriers (Fig. 1). The mean and SD of IFN-γ
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levels in 17 myelopathy patients (4,246 ± 2,924 pg/ml,
range: 375 to 10,750), was higher than that observed in 36
asymptomatic carriers (1,362 ± 1,408 pg/ml range: 15 to
6,995) or in 15 negative controls (1 ± 4 pg/ml), p = 0.0001,
Mann-Whitney U test. Evaluation of the frequency of
helminthes infection in 309 HTLV-I infected subjects re-
vealed that S. mansoni infection was 4.6 fold higher in
HTLV-I infected individuals (26/309 – 8.4%) than a com-
parable group of HTLV-I seronegative individuals (6/331
– 1.8%, p = 0.0003, Fisher’s exact test; data not shown).
With the aim to evaluate whether HTLV-I infection modify
the immune response in patients with S. mansoni, the lev-
els of IL-5 in co-infected patients were measured and com-
pared with IL-5 levels found in controls patients (schisto-
somiasis without HTLV-I infection) from an endemic area
of S. mansoni infection. The mean ± SD of IL-5 levels in
patients co-infected with S. mansoni and HTLV-1 was 258
± 692 pg/ml with variation of 0 – 2943 pg/ml. This value
was lower than (p < 0.05, Mann-Whitney U test) that ob-
served in patients only infected with S. mansoni (907 ±
1289 pg/ml with ranging of 0 – 4747 pg/ml (Fig. 2).
To evaluate the role of HTLV-I infection on antigen-
specific IgE levels in patients with schistosomiasis, the
distribution of the IgE, expressed in OD, in patients with
schistosomiasis without HTLV-I infection and in those
co-infected with HTLV-I was assayed (Fig. 3). The mean
IgE in 40 patients without HTLV-I infection was 0.195 +
0.169 compared to 0.123 + 0.04 in 22 patients with schisto-
somiasis associated with HTLV-I infection (p < 0.01, Mann
Whitney U test).
Fig. 1: interferon-γ (IFN-γ) levels (pg/ml) in HTLV-I-associated
myelopathy/tropical spastic paraparesis (HAM/TSP) (n = 17) pa-
tients compared with asymptomatic carries (n = 36) and negative
controls (n=15). The bars represent the median of IFN-γ concen-
trations and the difference were considered significant when p <
0.05 (Mann-Whitney U Test).
Fig. 2: HTLV-I down regulates IL-5 production to Schistosoma
mansoni antigen. IL-5 levels in peripheral blood mononuclear cells
stimulated with SWAP in S. mansoni and HTLV-1 co-infected pa-
tients (n = 22) and in chronic schistosomiasis patients (n = 44)
from an endemic area.
Fig. 3: SWAP-specific IgE from patients with Schistosoma mansoni
infection (n = 40) and S. mansoni co-infected with HTLV-I (n =
22).
Ultrasonography studies were used to further quan-
tify the observed clinical findings. The ultrasound find-
ings of 22 schistosomiasis patients co-infected with HTLV-
I and 40 schistosomiasis HTLV-I-seronegative controls
are shown in the Table. None of the 22 co-infected pa-
tients had splenomegaly (0/22), an index of severe hepatic
fibrosis. Only one case had mild hepatomegaly (1/22). In
contrast, age and sex-matched control schistosomiasis
HTLV-1-seronegative cases showed a significantly higher
frequency of clinical parameters for hepatic fibrosis. Sple-
nomegaly was observed in 2.5% (1/40) and hepatomegaly
was registered in 22% (9/40) of the HTLV-I-seronegative
schistosomiasis controls from Caatinga do Moura. An
absence of or a mild degree of fibrosis was noted in 21
schistosomiasis patients co-infected with HTLV-I stud-
ied by ultrasound. In contrast, 35% of the HTLV-I-serone-
gative schistosomiasis control group had degree II, evi-
dence of liver fibrosis that was significant different (p <
0.05, Fisher’s exact test) between the two groups.
To evaluate if helminthic infection may influence the
immunological response in individuals infected with HTLV-
I, the levels of IFN-γ were evaluated in HTLV-I carriers co-
infected with helminthes (S. stercoralis and/or S. mansoni)
and patients only infected with HTLV-I without any neu-
rological symptoms (HTLV-I asymptomatic). The levels
of IFN-γ in supernatants of lymphocyte cultures from
HTLV-I carriers with helminthic infection and without helm-
inthic infection are shown in Fig. 4. The IFN-γ levels (1,566
± 1,662 pg/ml) were higher in 35 HTLV-I patients without
helminthic infection than that observed in 35 patients with
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helminthic infection (893 ± 1,174 pg/ml, p < 0.05, Mann-
Whitney U test). Moreover there were less cells express-
ing IFN-γ and more cells expressing IL-10 in HTLV-I pa-
tients co-infected with helminths than in individuals only
infected with HTLV-I. Fig. 5 shows the frequency of CD8+
T cells secreting IFN-γ or IL-10 and the total frequency of
cells secreting IL-10 in unstimulated cultures of 4 HTLV-I
carriers co-infected with helminths and 7 HTLV-I carriers
without co-infection. Co-infection of HTLV-I with
helminthes significantly decreases the frequency of CD8
T cells secreting IFN-γ (p < 0.05). In contrast, the total
frequency of cells secreting IL-10 and the frequency of
CD8+ T cells secreting IL-10 was higher in HTLV-I indi-
viduals co-infected with helminthes (0.58%) in compari-
son with these only infected with HTLV-I (0.21%), p <
0.05.
stercoralis and/or S. mansoni) can down modulate the
exaggerated inflammatory response observed in HTLV-I
infected patients by reducing spontaneous IFN-γ syn-
thesis.
The pathogenesis of HAM/TSP is not completely
understood. Increased proviral load and the expansion of
HTLV-I tax-specific CD8+ cytotoxic T lymphocytes, both
in cerebrospinal fluid and in peripheral blood, have been
associated with the central nervous system involvement
in patients with HAM/TSP (Hanon et al. 2000, Kubota et
al. 2000, Nagai & Jacobson 2001). Moreover, many stud-
ies have demonstrated that pro-inflammatory cytokines
as IFN-γ, TNF-α, and IL-15 contribute to tissue damage
of the central nervous system of HAM/TSP patients
(Umehara et al. 1994, Biddison et al. 1997, Azimi et al. 2000).
Additionally, occurrence of fibrosis in neurological tis-
sue was also associated with the immunopathogenesis of
the neurological disease associated to HTLV-I (Nagai &
Jacobson 2001). Although the lymphocyte response was
quite variable in some HTLV-I asymptomatic carriers, our
date indicates a higher and significant  IFN-γ production
in HAM/TSP patients as compared to asymptomatic car-
riers. Although both type-1 and type-2 cytokines are found
to increase in unstimulated lymphocyte cultures of HTLV-
I infected individual when compared with controls
(Carvalho et al. 2001), this finding confirm an exacerbated
type-1 immune response in these HTLV-I infected sub-
jects
Schistosomiasis is one the most important helminthic
disease found in Northeast region of Brazil. Although the
majority of patients infected with S. mansoni have an in-
testinal or hepatointestinal form, liver fibrosis is observed
in 5% of patients with long-standing chronic S. mansoni
infection. Schistosomiasis is a well-characterized Th2 re-
sponse-dominated disease (Grzych et al. 1991). Immuno-
logical response in chronic schistosomiasis patients is
characterized by decreased IFN-γ production and en-
hancement in IL-4, IL-5, and IL-10 levels. This predomi-
nant type-2 immune response is independent of the de-
gree of infection measured by egg/stool gram and occurs
in all clinical form of schistosomiasis (de Jesus et al. 1993,
Araujo et al. 1996).
TABLE
Inverse association between human T cell leukemia virus-I
(HTLV-I) infection and liver fibrosis in patients with
schistosomiasis
                              Schistosomiasis groups
Clinical and HTLV-I HTLV-I-
ultrasonography co-infected non-infected
findings  (n = 20)  (n = 40)
Hepatomegaly    1/22 (4.5%)  9/40 (22%) a
Splenomegaly 0/22 (0%)   1/40 (2.5%) a
Ultrasound stage I    21/22 (95.5%) 26/40 (65%) a
Ultrasound stage II    1/20 (4.5%) 14/40 (35%) a
a: p < 0.05 (Fisher’s exact test)
Fig. 4: IFN-γ levels of HTLV-I infected patients (n = 35) co-in-
fected or not (n = 35) by helminthes (Strongyloides stercoralis and
Schistosoma mansoni).
Fig. 5: frequency of CD8+T cell secreting IFN-γ or IL-10 in HTLV-
I carriers co-infected with helmints (n = 4) and HTLV-I carriers
without co-infection with helmints (n = 7).
DISCUSSION
The present study shows that S. mansoni patients
co-infected with HTLV-I had their clinical and immuno-
logical parameters altered. Co-infection with HTLV-I sig-
nificantly decreases IL-5 levels, reduces the levels of para-
site-specific IgE and modifies the ultrasonography find-
ing characteristic of infected S. mansoni patients. By the
other hand, it is also shown that helminthes infections (S.
125Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 99(Suppl. I), 2004
High frequency of strongyloidiasis is registered in ar-
eas where both HTLV-I and S. stercoralis infection are
endemic (Nakada et al. 1984). Additionally, our finding
showed that the frequency of S. mansoni was increased
in HTLV-I infected patients when compared with HTLV-I
seronegative controls. Considering that no previous study
evaluated the impact of HTLV-I infection on S. mansoni
infection, we evaluated the changes in the immune re-
sponse to S. mansoni antigen in co-infected patients. We
observed that IL-5, a typical type-2 cytokine secreted in
schistosomiasis, was down regulated in S. mansoni pa-
tients co-infected with HTLV-I. In addition, we showed
that HTLV-I co-infection decrease the levels of SWAP-
specific IgE in S. mansoni infected patients. We have pre-
viously shown that HTLV-I decreases antigen specific
type-2 immune response in patients with S. stercoralis
infection (Neva et al. 1998, Porto et al. 2001a). Since there
is a tendency for an inverse correlation between IFN-γ
and IL-5 levels, it is possible that the down regulation of
IL-5 and specific-IgE levels is related to the enhancement
of type-1 pro-inflammatory cytokines synthesized during
HTLV-I infection.
The most severe form of S. mansoni infection is the
hepatosplenic form. Patients who develop this chronic
form show extensive liver fibrosis and hepatosplenom-
egaly. It is the parasite eggs that, by accumulating in the
liver, leading the granuloma formation.  Several factors
have been associated to liver fibrosis including the ge-
netic background, the degree of infestation and host im-
munological response. Initially, experimental studies sug-
gested that type-1 cytokines were associated with granu-
loma formation (Leptak & McKerrow 1997, Rezende et al.
1997). However, more recent date point to the importance
of type-2 cytokines such as IL-4 and IL-13 in inducing
fibrosis and the ability of IL-12 and IFN-γ to decrease it
(Wynn et al. 1994, Chiaramonte et al. 1999b, Jankovic
et al. 1999).
HTLV-I infection modifies the immune response to S.
mansoni antigen. It is possible that the HTLV-I co-infec-
tion also modify the clinical manifestation of schistoso-
miasis in these patients. When ultrasound of S. mansoni
and HTLV-I co-infected patients were compared with a
group of patients having only schistosomiasis but with
similar degree of infection than those dually co-infected,
the co-infected patients had significant lower liver fibro-
sis. In such case it is possible that the high type-1 im-
mune response observed by spontaneous IFN-γ produc-
tion in HTLV-I infection or the decrease of type-2 cytokines
are able to preventing the development of fibrosis in co-
infected patients.
By the other hand, the evaluation of the role of
helminthes infections (S. stercoralis and/or S. mansoni)
on the immune response of HTLV-I infected subjects with-
out symptoms showed that co-infection HTLV-I and
helminthes had immunological implications. The documen-
tation that IFN-γ levels decreased in HTLV-I carriers co-
infected with helminthes indicates that helmintic infec-
tion may down regulate IFN-γ production. It is probably
that helminthes down regulate IFN-γ production by in-
ducing secretion of IL-10. This date is consistent with the
date that show that exogenous IL-10 can decrease IFN-γ
production in lymphocytes cultures of HTLV-I carriers
(Carvalho et al. 2001). Together, these observations sug-
gest that HTLV-I alter the clinical and immunological find-
ings of HTLV-I and S. mansoni co-infection and those
HTLV-I individuals co-infected with S. stercoralis and/or
S. mansoni may decrease IFN-γ production and protect
HTLV-I carriers to develop diseases associated to HTLV-
I as HAM/TSP.
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